期刊文献+

调强放疗联合同步替吉奥化疗对复发直肠癌的疗效观察 被引量:4

暂未订购
导出
摘要 目的观察调强放疗联合同步替吉奥治疗复发直肠癌的近期疗效及并发症。方法对39例术后复发直肠癌患者采用调强放疗,每次1.8~2Gy,5次/周,预防剂量45~48Gy后推量至60~66Gy。同步口服替吉奥胶囊化疗,80mg/(m^2·d),分2次餐后1小时口服,周一至周五放疗时服用,观察治疗前后患者近期疗效、放化疗反应毒性。结果有36例完成治疗,依从性好,有效率为87.2%,疾病控制率为100%。主要毒副反应为消化道反应、血液学毒性、肛周皮肤反应,多为1、2级。结论调强放疗联合替吉奥对复发直肠癌的近期疗效较好。
作者 高利民
出处 《中国临床医生杂志》 2016年第9期62-63,共2页 Chinese Journal For Clinicians
  • 相关文献

参考文献16

二级参考文献81

  • 1聂立功,王广发.肺癌的个体化治疗[J].中国医学前沿杂志(电子版),2014,6(2):17-18. 被引量:12
  • 2邓艳红,詹文华.结直肠癌新辅助治疗的新进展[J].中国实用外科杂志,2005,25(5):310-312. 被引量:21
  • 3Shirasaka T,Shimamoto Y,Ohshimo H,et al[J].Development of a novel form of an oral S-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators[J].Anticancer Drugs,1996; 7; 548 -557.
  • 4Ikeda K,Yoshisue K,Matsushima E,et al.Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P -450 2A6 in human liver microsomes in vitro[J].Clin Cancer Res,2000; 6:4409 -4415.
  • 5Tatsumi K,Fukushima M,Shirasaka T,et al.Inhibitory effects of pyrimidine,barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rats liver extracts[J].Jpn J Cancer Res,1987; 78:748-755.
  • 6Shirasaka T,Shimamoto Y,Fukushima M.Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats[J].Cancer Res,1993 ;53:4004-4009.
  • 7Shirasaka T.Development history and concept of an oral anticancer agent S-1 (TS-1):Its clinical usefulness and future vistas[J].Jpn J Clin Oncol,2009; 39:2 -15.
  • 8Hirata K,Horikoshi N,Aiba K,et al.Pharmacokinetic study of S -1,a novel oral fluorouracil antitumor drug[J].Clin Cancer Res,1999;5:2000-2005.
  • 9Peters GJ,Noordhuis P,van Kuilenburget AB,et al.Pharmacoki-netics of S -1,an oral formulation of ftorafur,oxonic acid and S -chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors[J].Cancer Chemother Pharmacol,2003; 52:1 -12.
  • 10Hoff PM,Saad ED,Ajani JA,et al.Phase I study with pharmaco-kinetics of S-1,an oral daily schedule for 28 days in patients with solid tumors[J].Clin Cancer Res,2003 ; 9:134 -142.

共引文献82

同被引文献33

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部